Posted by Michael Wonder on 15 Nov 2024
Leo Pharma’s Anzupgo (delgocitinib) cream achieves marketing approval in Switzerland
14 November 2024 - In addition to the results of the DELTA 1,2 and 3 trials, the marketing approval is supported by the head to head DELTA FORCE trial of Anzupgo against oral alitretinoin capsules, the only other existing specifically approved treatment for severe chronic hand eczema.
Leo Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream.
